Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HNF4A | P41235 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LIG1 | P18858 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14937360 | 0.85 | PARP1 (0.41) | PARP1HSD17B10HNF4AALDH1A1L3MBTL1 | |
| SCHEMBL20510040 | 0.76 | PARP1 (0.73) | PARP1HSD17B10HNF4AALDH1A1L3MBTL1 | |
| SCHEMBL436709 | 0.74 | PARP1 (0.40) | PARP1HSD17B10HNF4AALDH1A1L3MBTL1 | |
| SCHEMBL11094419 | 0.70 | PARP1 (0.49) | PARP1HSD17B10ALDH1A1MAPTALOX15 | |
| SCHEMBL436710 | 0.68 | HSD17B10 (0.36) | HSD17B10HNF4AALDH1A1L3MBTL1MAPT | |
| SCHEMBL6836766 | 0.67 | PARP1 (0.51) | PARP1HSD17B10HNF4AALDH1A1L3MBTL1 | |
| SCHEMBL5449123 | 0.64 | ALDH1A1 (0.44) | PARP1HSD17B10HNF4AALDH1A1L3MBTL1 | |
| SCHEMBL28290216 | 0.64 | MYC (0.49) | HNF4AALDH1A1L3MBTL1MYCLMNA | |
| SCHEMBL31364686 | 0.62 | SMYD3 (0.57) | PARP1ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL251991 | 0.61 | KDM4E (0.56) | PARP1HSD17B10ALDH1A1ALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595988-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | claimed |
| US-20230404963-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CD4/6 INHIBITORS FOR THE TREATMENT OF CANCER | SYNDEVRX, INC. | 2023-12-21 | — | — | US | disclosed |
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-9266896-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2595988-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230404963-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CD4/6 INHIBITORS FOR THE TREATMENT OF CANCER | CDK6, MPHOSPH6, CD4 | PARP1 876/4885HSD17B10 4634/4885HNF4A 1404/4885 |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | CES2, DNPEP, METAP2 | PARP1 988/4885HSD17B10 328/4885HNF4A 3112/4885 |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | CES2, DNPEP, METAP2 | PARP1 988/4885HSD17B10 328/4885HNF4A 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.